Influence of Genotype and Haplotype of MDR1 (C3435T, G2677A/T, C1236T) on the Incidence of Breast Cancer - a Case-Control Study in Jordan

  • Abuhaliema, Ali M (Department of Biopharmaceutics and Clinical Pharmacy, Faculty of Pharmacy, the University of Jordan) ;
  • Yousef, Al-Motassem F (Department of Biopharmaceutics and Clinical Pharmacy, Faculty of Pharmacy, the University of Jordan) ;
  • El-Madany, Nirmeen N (Department of Biopharmaceutics and Clinical Pharmacy, Faculty of Pharmacy, the University of Jordan) ;
  • Bulatova, Nailya R (Department of Biopharmaceutics and Clinical Pharmacy, Faculty of Pharmacy, the University of Jordan) ;
  • Awwad, Nemah M (Department of Biopharmaceutics and Clinical Pharmacy, Faculty of Pharmacy, the University of Jordan) ;
  • Yousef, Muhammad A (Department of Biopharmaceutics and Clinical Pharmacy, Faculty of Pharmacy, the University of Jordan) ;
  • Al Majdalawi, Khalil Z (Department of Biopharmaceutics and Clinical Pharmacy, Faculty of Pharmacy, the University of Jordan)
  • Published : 2016.02.05


Background: Breast cancer is the leading cause of cancer death among women and the second in humans worldwide. Many published studies have suggested an association between MDR1 polymorphisms and breast cancer risk. Our aim was to study the association between genetic polymorphism of MDR1 at three sites (C3435T, G2677A/T, and C1236T) and their haplotype and the risk of breast cancer in Jordanian females. Materials and Methods: A case-control study involving 150 breast cancer cases and 150 controls was conducted. Controls were age-matched to cases. The polymerase chain reaction/restriction fragment length polymorphism (PCR-RFLP) technique and sequencing were performed to analyse genotypes. Results: The distribution of MDR1 C3435T genotypes differed between cases and controls [cases, CC 45.3%, CT 41.3%, and TT 13.3%; controls, CC 13.4%, CT 43.3%, and TT 30.2%, p < 0.001]. Similarly, the distribution of G2677A/T significantly differed [cases, GG 43.1 %, GT+GA 50.9% and AA+TT 6%; controls, GG 29.6 %, GT+GA 50.9%, and AA+TT 19.4%, p = 0.004]. On the other hand, genotype and allelotype distribution of C1236T was not statistically different between cases and controls (p=0.56 and 0.26, respectively). The CGC haplotype increased the risk to breast cancer by 2.5-fold compared to others, while TGC and TTC haplotypes carried 2.5- and 5-fold lower risk of breast cancer, respectively. Conclusions: Genetic polymorphisms of MDR1 C3435T and G2677A/T, but not C1236T, are associated with increased risk of breast cancer. In addition, CGC, TGC and TTC haplotypes have different impacts on the risk of breast cancer. Future, larger studies are needed to validate these findings.


Breast cancer;MDR1;polymorphism;haplotype;Jordan


Supported by : The University of Jordan


  1. Tulsyan S, Chaturvedi P, Singh AK, et al (2014). Assessment of clinical outcomes in breast cancer patients treated with taxanes: multi-analytical approach. Gene, 543, 69-75.
  2. Wang J, Wang B, Bi J, et al (2012). MDR1 gene C3435T polymorphism and cancer risk: a meta-analysis of 34 casecontrol studies. J Cancer Res Clin Oncol, 138, 979-89.
  3. Wang LH, Song YB, Zheng WL, et al (2013a). The association between polymorphisms in the MDR1 gene and risk of cancer: a systematic review and pooled analysis of 52 casecontrol studies. Cancer Cell Int, 13, 46.
  4. Wang Z, Wang T, Bian J (2013b). Association between MDR1 C3435T polymorphism and risk of breast cancer. Gene, 532, 94-9.
  5. Wu H, Kang H, Liu Y, et al (2012). Roles of ABCB1 gene polymorphisms and haplotype in susceptibility to breast carcinoma risk and clinical outcomes. J Cancer Res Clin Oncol, 138, 1449-62.
  6. Zhu CY, Lv YP, Yan DF, et al (2013). Knockdown of MDR1 increases the sensitivity to adriamycin in drug resistant gastric cancer cells. Asian Pac J Cancer Prev, 14, 6757-60.
  7. Zubor P, Lasabova Z, Hatok J, et al (2007). A polymorphism C3435T of the MDR-1 gene associated with smoking or high body mass index increases the risk of sporadic breast cancer in women. Oncol Rep, 18, 211-7.
  8. Alsaif AA, Hasan TN, Shafi G, et al (2013). Association of multiple drug resistance-1 gene polymorphism with multiple drug resistance in breast cancer patients from an ethnic Saudi Arabian population. Cancer Epidemiol, 37, 762-6.
  9. Awwad N, Yousef AM, Abuhaliema A, et al (2015). Relationship between Genetic Polymorphisms in MTHFR (C677T, A1298C and their Haplotypes) and the Incidence Of Breast Cancer among Jordanian Females--Case-Control Study. Asian Pac J Cancer Prev, 16, 5007-11.
  10. Barrett JC, Fry B, Maller J, et al (2005). Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics, 21, 263-5.
  11. Al-Diab O, Yousef A-M, Al Manassrah E, et al (2015). Genotype and Haplotype analysis of ABCB1 at 1236, 2677 and 3435 among Jordanian population. Trop J Pharm Res, 14, 1013-9.
  12. Al Rifai RO, Nakamura K (2015). Differences in breast and cervical cancer screening rates in Jordan among Women from different socioeconomic strata: analysis of the 2012 population-based household survey. Asian Pac J Cancer Prev, 16, 6697-704.
  13. Cochran G (1954). Some methods for strengthening the common ${\chi}$ tests. Biometrics, 10, 417-51.
  14. de Oliveira J, Felipe AV, Neto RA, et al (2014). Association between ABCB1 immunohistochemical expression and overall survival in gastric cancer patients. Asian Pac J Cancer Prev, 15, 6935-8.
  15. Du Y, Su T, Zhao L, et al (2014). Associations of polymorphisms in DNA repair genes and MDR1 gene with chemotherapy response and survival of non-small cell lung cancer.
  16. Fawzy MS, Awad HA, Ahmad HS, et al (2014). Multi-drug resistance 1 genetic polymorphisms gene expression and prediction of chemotherapy response in breast cancer Egyptian patients. Egypt J Biochem Mol Biol, 32, 75-98.
  17. Gaunt TR, Rodriguez S, Zapata C, et al (2006). MIDAS: software for analysis and visualisation of interallelic disequilibrium between multiallelic markers. BMC Bioinformatics, 7, 227.
  18. Global Health Estimates, WHO. 2013. [Accessed 14 June 2015].
  19. Gutierrez-Rubio SA, Quintero-Ramos A, Duran-Cardenas A, et al (2015). 1236 C/T and 3435 C/T polymorphisms of the ABCB1 gene in Mexican breast cancer patients. Genet Mol Res, 14, 1250-9.
  20. Hamidovic A, Hahn K, Kolesar J (2010). Clinical significance of ABCB1 genotyping in oncology. J Oncol Pharm Pract, 16, 39-44.
  21. Henriquez-Hernandez LA, Murias-Rosales A, Hernandez Gonzalez A, et al (2009). Gene polymorphisms in TYMS, MTHFR, p53 and MDR1 as risk factors for breast cancer: a case-control study. Oncol Rep, 22, 1425-33.
  22. Ikeda M, Tsuji D, Yamamoto K, et al (2015). Relationship between ABCB1 gene polymorphisms and severe neutropenia in patients with breast cancer treated with doxorubicin/cyclophosphamide chemotherapy. Drug Metab Pharmacokinet, 30, 149-53.
  23. Ji M, Tang J, Zhao J, et al (2012). Polymorphisms in genes involved in drug detoxification and clinical outcomes of anthracycline-based neoadjuvant chemotherapy in Chinese Han breast cancer patients. Cancer Biol Ther, 13, 264-71.
  24. Kalinsky K, Mayer JA, Xu X, et al (2015). Correlation of hormone receptor status between circulating tumor cells, primary tumor, and metastasis in breast cancer patients. Clin Transl Oncol, 17, 539-46.
  25. Kim HJ, Im SA, Keam B, et al (2015). ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy. Cancer Sci, 106, 86-93.
  26. Kim JL, Cho KH, Park EC, et al (2014). A single measure of cancer burden combining incidence with mortality rates for worldwide application. Asian Pac J Cancer Prev, 15, 433-9.
  27. Kreile M, Rots D, Piekuse L, et al (2014). Lack of association between polymorphisms in genes MTHFR and MDR1 with risk of childhood acute lymphoblastic leukemia. Asian Pac J Cancer Prev, 15, 9707-11.
  28. Lecarpentier J, Nogues C, Mouret-Fourme E, et al (2015). Breast cancer risk associated with estrogen exposure and truncating mutation location in BRCA1/2 Carriers. Cancer Epidemiol Biomarkers Prev, 24, 698-707.
  29. Lu PH, Wei MX, Yang J, et al (2011). Association between two polymorphisms of ABCB1 and breast cancer risk in the current studies: a meta-analysis. Breast Cancer Res Treat, 125, 537-43.
  30. Macias-Gomez NM, Gutierrez-Angulo M, Leal-Ugarte E, et al (2014). MDR1 C3435T polymorphism in Mexican patients with breast cancer. Genet Mol Res, 13, 5018-24.
  31. Ozdemir S, Uludag A, Silan F, et al (2013). Possible roles of the xenobiotic transporter P-glycoproteins encoded by the MDR1 3435 C>T gene polymorphism in differentiated thyroid cancers. Asian Pac J Cancer Prev, 14, 3213-7.
  32. Payandeh M, Sadeghi M, Sadeghi E (2015). Differences in prognostic factors between early and late recurrence breast cancers. Asian Pac J Cancer Prev, 16, 6575-9.
  33. Pongstaporn W, Pakakasama S, Chaksangchaichote P, et al (2015). MDR1 C3435T and C1236T polymorphisms: association with high-risk childhood acute lymphoblastic leukemia. Asian Pac J Cancer Prev, 16, 2839-43.
  34. Rodriguez S, Gaunt TR, Day IN (2009). Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am J Epidemiol, 169, 505-14.
  35. Rubis B, Holysz H, Barczak W, et al (2012). Study of ABCB1 polymorphism frequency in breast cancer patients from Poland. Pharmacol Rep, 64, 1560-6.
  36. Salem AH, Ali M, Ibrahim A, et al (2014). Genotype and Allele Frequencies of MDR-1 Gene Polymorphism in Jordanian and Sudanese Populations. American Journal of Medicine Studies, 2, 19-23.
  37. Sufian SN, Masroor I, Mirza W, et al (2015). Evaluation of common risk factors for breast carcinoma in females: a hospital based study in karachi, Pakistan. Asian Pac J Cancer Prev, 16, 6347-52.

Cited by

  1. Association between ABCB1 C3435T polymorphism and breast cancer risk: a Moroccan case-control study and meta-analysis vol.17, pp.1, 2016,
  2. The risk of clopidogrel resistance is associated with ABCB1 polymorphisms but not promoter methylation in a Chinese Han population vol.12, pp.3, 2017,
  3. Impact of Genetic Polymorphisms on Phenytoin Pharmacokinetics and Clinical Outcomes in the Middle East and North Africa Region vol.17, pp.3, 2017,
  4. Interactions Between ABCB1 Genotype and Preoperative Statin Use Impact Clinical Outcomes Among Breast Cancer Patients vol.8, pp.2234-943X, 2018,